title: Persistent seropositivity for yellow fever in a previously vaccinated autologous hematopoietic stem cell transplantation recipient.
abstract: The duration of a protective level of yellow fever antibodies after autologous hematopoietic stem cell transplantation in a previously vaccinated person is unclear. The case of a patient who had previously been vaccinated for yellow fever and who remained seropositive for 22 months after autologous peripheral blood stem cell transplantation for malignant lymphoma is described herein.
authors.affiliation: Disease Control and Prevention Center, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, Japan. Electronic address: kayokohayakawa@gmail.com.
authors.forename: Kayoko
authors.initials: K
authors.lastname: Hayakawa
authors.affiliation: Department of Virology 1, National Institute of Infectious Diseases, Shinjuku-ku, Tokyo, Japan.
authors.forename: Tomohiko
authors.initials: T
authors.lastname: Takasaki
authors.affiliation: Department of Hematology, Shinko Hospital, Kobe, Japan.
authors.forename: Hiroko
authors.initials: H
authors.lastname: Tsunemine
authors.affiliation: Disease Control and Prevention Center, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, Japan.
authors.forename: Shuzo
authors.initials: S
authors.lastname: Kanagawa
authors.affiliation: Disease Control and Prevention Center, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, Japan.
authors.forename: Satoshi
authors.initials: S
authors.lastname: Kutsuna
authors.affiliation: Disease Control and Prevention Center, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, Japan.
authors.forename: Nozomi
authors.initials: N
authors.lastname: Takeshita
authors.affiliation: Disease Control and Prevention Center, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, Japan.
authors.forename: Momoko
authors.initials: M
authors.lastname: Mawatari
authors.affiliation: Disease Control and Prevention Center, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, Japan.
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Fujiya
authors.affiliation: Disease Control and Prevention Center, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, Japan.
authors.forename: Kei
authors.initials: K
authors.lastname: Yamamoto
authors.affiliation: Disease Control and Prevention Center, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, Japan.
authors.forename: Norio
authors.initials: N
authors.lastname: Ohmagari
authors.affiliation: Disease Control and Prevention Center, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, Japan.
authors.forename: Yasuyuki
authors.initials: Y
authors.lastname: Kato
mesh_terms: D000914:Antibodies, Viral / Q000097:blood; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007565:Jaundice / Q000276:immunology / Q000517:prevention & control / Q000821:virology*; D008223:Lymphoma / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D014182:Transplantation, Autologous; D014611:Vaccination; D015004:Yellow Fever / Q000276:immunology*; D022341:Yellow Fever Vaccine / Q000008:administration & dosage / Q000276:immunology*
chemical_list: D000914:Antibodies, Viral; D022341:Yellow Fever Vaccine
keywords: Autologous hematopoietic stem cell transplantation; Bone marrow transplantation; Seropositivity; Vaccination; Yellow fever